What a fantastic presentation and a clear & concise way to portray the insane demand tailwinds behind this company.
From a cash perspective, its worth noting that they projected to be Cash Flow Positive this Qtr (from last 4C) so there is no CR on its way... All the demand / sales from China is based on a cash-upfront basis. So they physically get the cash from their customer before packing/shipping the goods.
UCM has been under the radar of the investment community for some time as it's required a lot of 'joining the dots' for new investors & lets face it, many of us are lazy.
I outlined in a previous post why I thought it was a slam-dunk (here - https://hotcopper.com.au/threads/cl....5246113/page-2?post_id=43134880#.Xlg5E2cViJA) after Rob did a media interview.
The below slide (Slide 13) also outlines what Rob was explaining in the interview:
From the presentation today, the following chestnuts stand out as very bullish indicators for the company. (Slide 10 extract below)
So USCOM Technology has been specifically recommended by the Chinese Government Coronavirus Guidelines
Slide 11 & 12 extracts (below) outlines how their technology supports Cardiovascular systems and their non-invasive, dopplar nature mean that it's world class, patent protected, FDA / NMPA approved & without competition
Finally - We are all eagerly awaiting a further update on their sales / orders which have been significantly boosted from this outbreak. The last outbreak we received was on 10-Feb for the first 5 weeks of the calendar year which showed a 121% increase in sales over the PcP.
Furthermore, in that release, they note that the first device specifically commissioned on 23rd Jan 2020
Given the deadline for the half-yearly reports is prior to the commencement of trade Monday morning, I am betting that we get a sales further sales update with those accounts.
So that could land anytime today, but before trading commences Monday
I'm a happy little holder of this gem!
Add to My Watchlist
What is My Watchlist?
